New small-molecule inhibitors effectively blocking picornavirus replication

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11091-11107

  Siltz, Lauren A Ford ^a   Viktorova, Ekaterina G ^a   Zhang, Ben ^b   Kouiavskaia, Diana ^c   Dragunsky, Eugenia ^c   Chumakov, Konstantin ^c   Isaacs, Lyle ^b   Belov, George A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b Bldg 142   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT INHIBITOR IV; INDIRUBIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR III; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; PHOSPHATIDYLINOSITOL KINASE; POLYPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; COXSACKIE VIRUS B3; DRUG STRUCTURE; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; IN VITRO STUDY; LIFE CYCLE STAGE; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PROTEIN PROCESSING; RNA TRANSLATION; TOXICITY TESTING; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; ANIMAL; CELL FREE SYSTEM; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENTEROVIRUS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELA CELL LINE; HUMAN; METABOLISM; MOLECULAR LIBRARY; MUTATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VIROLOGY;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANIMALS; ANTIVIRAL AGENTS; CELL-FREE SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALOMYOCARDITIS VIRUS; ENTEROVIRUS B, HUMAN; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HUMANS; MICE; MUTATION; POLIOMYELITIS; POLIOVIRUS; POLYPROTEINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84906974420     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01877-14     Document Type: Article

References (53)

1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. 2003. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med. 163:487-494. http://dx.doi.org/10.1001/archinte.163.4.487.
2. Bertino JS. 2002. Cost burden of viral respiratory infections: issues for formulary decision makers. Am. J. Med. 112(Suppl 6A):42S-49S. http://dx.doi.org/10.1016/S0002-9343(01)01063-4.
3. Arden KE, Mackay IM. 2009. Human rhinoviruses: coming in from the cold. Genome Med. 1:44. http://dx.doi.org/10.1186/gm44.
4. Fujinami RS, von Herrath MG, Christen U, Whitton JL. 2006. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. 19:80-94. http://dx.doi.org/10.1128/CMR.19.1.80-94.2006.
5. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. 2005. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 111:887-893. http://dx.doi.org/10.1161/01.CIR.0000155616.07901.35.
6. Yeung WC, Rawlinson WD, Craig ME. 2011. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342:d35. http://dx.doi.org/10.1136/bmj .d35.
7. Collett MS, Neyts J, Modlin JF. 2008. A case for developing antiviral drugs against polio. Antiviral Res. 79:179-187. http://dx.doi.org/10.1016/j.antiviral.2008.04.002.
8. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289- 7294. http://dx.doi.org/10.1073/pnas.1232294100.
9. Crotty S, Saleh MC, Gitlin L, Beske O, Andino R. 2004. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J. Virol. 78:3378-3386. http://dx.doi.org/10.1128/JVI.78.7.3378-3386.2004.
10. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85:2364-2372. http://dx.doi.org/10.1128/JVI.02249-10.
11. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83: 185-192. http://dx.doi.org/10.1016/j.bcp.2011.08.016.
12. Geller R, Vignuzzi M, Andino R, Frydman J. 2007. Evolutionary con-straints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21:195-205. http://dx.doi.org/10.1101/gad.1505307.
13. Belov GA, Nair V, Hansen BT, Hoyt FH, Fischer ER, Ehrenfeld E. 2012. Complex dynamic development of poliovirus membranous replication complexes. J. Virol. 86:302-312. http://dx.doi.org/10.1128/JVI.05937-11.
14. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2013. Oxysterol-binding protein family I is the target of minor enviroximelike compounds. J. Virol. 87:4252- 4260. http://dx.doi.org/10.1128/JVI.03546-12.
15. Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJ, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811. http://dx.doi.org/10.1016/j.cell.2010.03.050.
16. Belov GA, Altan-Bonnet N, Kovtunovych G, Jackson CL, Lippincott-Schwartz J, Ehrenfeld E. 2007. Hijacking components of the cellular secretory pathway for replication of poliovirus RNA. J. Virol. 81:558-567. http://dx.doi.org/10.1128/JVI.01820-06.
17. Herold J, Andino R. 2000. Poliovirus requires a precise 5= end for efficient positive-strand RNA synthesis. J. Virol. 74:6394-6400. http://dx.doi.org/10.1128/JVI.74.14.6394-6400.2000.
18. Belov GA, Fogg MH, Ehrenfeld E. 2005. Poliovirus proteins induce membrane association of GTPase ADP-ribosylation factor. J. Virol. 79: 7207-7216. http://dx.doi.org/10.1128/JVI.79.11.7207-7216.2005.
19. Fogg MH, Teterina NL, Ehrenfeld E. 2003. Membrane requirements for uridylylation of the poliovirus VPg protein and viral RNA synthesis in vitro. J. Virol. 77:11408 -11416. http://dx.doi.org/10.1128/JVI.77.21.11408-11416.2003.
20. Teterina NL, Rinaudo MS, Ehrenfeld E. 2003. Strand-specific RNA synthesis defects in a poliovirus with a mutation in protein 3A. J. Virol. 77:12679-12691. http://dx.doi.org/10.1128/JVI.77.23.12679-12691.2003.
21. Ma D, Hettiarachchi G, Nguyen D, Zhang B, Wittenberg JB, Zavalij PY, Briken V, Isaacs L. 2012. Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals. Nat. Chem. 4:503-510. http://dx.doi.org/10.1038/nchem.1326.
22. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, Nomoto A. 1991. Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 88:951-955. http://dx.doi.org/10.1073/pnas.88.3.951.
23. Koike S, Taya C, Aoki J, Matsuda Y, Ise I, Takeda H, Matsuzaki T, Amanuma H, Yonekawa H, Nomoto A. 1994. Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene-influence of the transgene expression on pathogenesis. Arch. Virol. 139:351-363. http://dx.doi.org/10.1007/BF01310797.
24. Irurzun A, Perez L, Carrasco L. 1992. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166-175. http://dx.doi.org/10.1016/0042-6822(92)90178-R.
25. Maynell LA, Kirkegaard K, Klymkowsky MW. 1992. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66:1985-1994.
26. Belov GA, Romanova LI, Tolskaya EA, Kolesnikova MS, Lazebnik YA, Agol VI. 2003. The major apoptotic pathway activated and suppressed by poliovirus. J. Virol. 77:45-56. http://dx.doi.org/10.1128/JVI.77.1.45-56.2003.
27. Arita M, Wakita T, Shimizu H. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90:1869-1879. http://dx.doi.org/10.1099/vir.0.012096-0.
28. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. 2003. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4:463-476. http://dx.doi.org/10.1016/S1535-6108(03)00303-9.
29. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. 2004. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64:4394-4399. http://dx.doi.org/10.1158/0008-5472.CAN-04-0343.
30. Feldman ME, Shokat KM. 2011. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs). Curr. Top. Microbiol. 347:241- 262. http://dx.doi.org/10.1007/82_2010_64.
31. Matsuno K, Ushiki J, Seishi T, Ichimura M, Giese NA, Yu JC, Takahashi S, Oda S, Nomoto Y. 2003. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J. Med. Chem. 46:4910 - 4925. http://dx.doi.org/10.1021/jm020505v.
32. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. 2005. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 102:5998-6003. http://dx.doi.org/10.1073/pnas.0409467102.
33. Barton DJ, Black EP, Flanegan JB. 1995. Complete replication of poliovirus in vitro: preinitiation RNA replication complexes require soluble cellular factors for the synthesis of VPg-linked RNA. J. Virol. 69:5516- 5527.
34. Barton DJ, Morasco BJ, Flanegan JB. 1999. Translating ribosomes inhibit poliovirus negative-strand RNA synthesis. J. Virol. 73:10104-10112.
35. Lanke KH, van der Schaar HM, Belov GA, Feng Q, Duijsings D, Jackson CL, Ehrenfeld E, van Kuppeveld FJ. 2009. GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3RNAreplication. J. Virol. 83:11940-11949. http://dx.doi.org/10.1128/JVI.01244-09.
36. Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4:e1000216. http://dx.doi.org/10.1371/journal.ppat.1000216.
37. Wessels E, Duijsings D, Lanke KH, Melchers WJ, Jackson CL, van Kuppeveld FJ. 2007. Molecular determinants of the interaction between coxsackievirus protein 3A and guanine nucleotide exchange factor GBF1. J. Virol. 81:5238-5245. http://dx.doi.org/10.1128/JVI.02680-06.
38. Wessels E, Duijsings D, Niu TK, Neumann S, Oorschot VM, de Lange F, Lanke KH, Klumperman J, Henke A, Jackson CL, Melchers WJ, van Kuppeveld FJ. 2006. A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev. Cell 11:191-201. http://dx.doi.org/10.1016/j.devcel.2006.06.005.
39. Dorobantu CM, van der Schaar HM, Ford LA, Strating JR, Ulferts R, Fang Y, Belov G, van Kuppeveld FJ. 2014. Recruitment of PI4KIIIbeta to coxsackievirus B3 replication organelles is independent of ACBD3, GBF1, and Arf1. J. Virol. 88:2725-2736. http://dx.doi.org/10.1128/JVI.03650-13.
40. Sasaki J, Ishikawa K, Arita M, Taniguchi K. 2012. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J. 31:754-766. http://dx.doi.org/10.1038/emboj.2011.429.
41. Greninger AL, Knudsen GM, Betegon M, Burlingame AL, Derisi JL. 2012. The 3A protein from multiple picornaviruses utilizes the Golgi adaptor protein ACBD3 to recruit PI4KIIIbeta. J. Virol. 86:3605-3616. http://dx.doi.org/10.1128/JVI.06778-11.
42. Teoule F, Brisac C, Pelletier I, Vidalain PO, Jegouic S, Mirabelli C, Bessaud M, Combelas N, Autret A, Tangy F, Delpeyroux F, Blondel B. 2013. The Golgi protein ACBD3, an interactor for poliovirus protein 3A, modulates poliovirus replication. J. Virol. 87:11031-11046. http://dx.doi.org/10.1128/JVI.00304-13.
43. Arita M, Takebe Y, Wakita T, Shimizu H. 2010. A bifunctional antienterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J. Gen. Virol. 91:2734-2744. http://dx.doi.org/10.1099/vir.0.023374-0.
44. Heinz BA, Vance LM. 1996. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J. Virol. 70: 4854-4857.
45. van der Schaar HM, Leyssen P, Thibaut HJ, de Palma A, van der Linden L, Lanke KH, Lacroix C, Verbeken E, Conrath K, Macleod AM, Mitchell DR, Palmer NJ, van de Poel H, Andrews M, Neyts J, van Kuppeveld FJ. 2013. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIbeta. Antimicrob. Agents Chemother. 57:4971- 4981. http://dx.doi.org/10.1128/AAC.01175-13.
46. van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Purstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ. 2012. Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication. Cell Res. 22:1576-1592. http://dx.doi.org/10.1038/cr.2012.129.
47. Barton DJ, Flanegan JB. 1997. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidineinhibited activity of protein 2C. J. Virol. 71:8482-8489.
48. Pfister T, Wimmer E. 1999. Characterization of the nucleoside triphos-phatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J. Biol. Chem. 274:6992-7001. http://dx.doi.org/10.1074/jbc.274.11.6992.
49. McCormick W, Penman S. 1968. Replication of mengovirus in HeLa cells preinfected with nonreplicating poliovirus. J. Virol. 2:859-864.
50. Prather SO, Taylor MW. 1975. Host-dependent restriction of mengovirus replication. IV. Effect of some quaternary ammonium ions on the restricted replication of mengovirus in Madin-Darby bovine kidney cells. J. Virol. 15:1033-1036.
51. Gazina EV, Mackenzie JM, Gorrell RJ, Anderson DA. 2002. Differential requirements for COPI coats in formation of replication complexes among three genera of Picornaviridae. J. Virol. 76:11113-11122. http://dx.doi.org/10.1128/JVI.76.21.11113-11122.2002.
52. Cuconati A, Molla A, Wimmer E. 1998. Brefeldin A inhibits cell-free, de novo synthesis of poliovirus. J. Virol. 72:6456-6464.
53. Dunn EF, Fearns R, Connor JH. 2009. Akt inhibitor Akt-IV blocks virus replication through an Akt-independent mechanism. J. Virol. 83:11665- 11672. http://dx.doi.org/10.1128/JVI.01092-09.